Additional data supporting the potential utility of RPL554 in Cystic Fibrosis (CF) has been announced and presented at a conference in the US. CF is an inherited life-threatening Orphan disease with around 70,000 people afflicted worldwide. The data is encouraging and Verona plans to undertake additional studies in 2016 to continue to explore RPL554’s potential in CF. The pre-clinical data follows the unequivocally positive results from the third and final part of its Phase I/IIa trial of RPL554 ....
